The cellular mechanisms involved in the asymmetric facial overgrowth syndrome, hemifacial hyperplasia (HFH), are not well understood. This study was conducted to compare primary cell cultures from hyperplastic and normal HFH bone for cellular and molecular differences. Primary cultures developed from biopsies of a patient with isolated HFH showed a twofold difference in cell size and cell number between hyperplastic and normal bone. Microarray data suggested a 40% suppression of PTEN (phosphatase-tensin homolog) transcripts. Sequencing of the PTEN gene and promoter identified novel C/G missense mutation (position À 1053) in the regulatory region of the PTEN promoter. Western blots of downstream pathway components showed an increase in PKBa/Akt1 phosphorylation and TOR (target of rapamcyin) signal. Sirolimus, an inhibitor of TOR, when added to overgrowth cells reversed the cell size, cell number and total protein differences between hyperplastic and normal cells. In cases of facial overgrowth, which involve PTEN/Akt/TOR dysregulation, sirolimus could be used for limiting cell overgrowth.
Introduction
Isolated hemifacial hyperplasia (HFH) is [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] a rare condition of asymmetric facial growth occurring in 1/14 000-1/86 000 live births. It is also known as hemihypertrophy 15 and is sometimes associated with the Beckwith-Wiedemann syndrome, neurofibromatosis, the Proteus syndrome, the Klipper-TrenaunayWeber syndrome and tumors of the liver, adrenal gland or kidney. The molecular etiology for HFH is not known (AHC (MIM: 235000)). Current treatments are based on surgically reducing the facial asymmetry and overgrown tissues, which can include the frontal bone, maxilla, palate, mandible, alveolar process, tongue, and teeth and associated soft tissues. 15, 16 As the facial features of HFH are similar to a group of facial hamartoma-like syndromes associated with an epidermal nevus ( Figure 1) , 17, 18 one approach to understanding these disorder tests whether mutations in the tumor suppressor gene PTEN (phosphatase-tensin homolog) may be common to all syndromes of hamartomatous overgrowth. 19 Germline PTEN mutations have been reported in 85% of the Cowden syndrome, 65% of the Bannayan-Riley-Ruvalcaba syndrome, 20 20% of the Proteus syndrome and 50% of the Proteus-like syndromes. 20, 21 PTEN is an important regulator of cell growth via the insulin/insulin growth factor-I (IGF-I) and -II pathway as it can suppress cell growth via the PI3K/Akt pathway by decreasing phosphatidylinositol-3,4,5 triphosphate levels, which results in decreased Akt phosphorylation. 22 PTEN can also cause G 1 cell arrest and apoptosis in many cell types. 23, 24 When PTEN is mutated or suppressed, Akt is inappropriately activated and signals the cell proliferation noted in many types of tumors.
A downstream component of the PI3K/Akt pathway is TOR (target of rapamcyin), which is a determinant of cell size in Caenorhabditiselegans, Drosophila and mouse models. [25] [26] [27] This study was conducted to develop a cell culture model for HFH by developing primary cultures from bone biopsies. Significant cell growth differences were retained in primary cultures derived from normal and overgrowth bone biopsies, as were alterations in PTEN, Akt and TOR signaling. In addition, the cell overgrowth, cell proliferation and increased protein content observed on the overgrown side were rescued by adding Sirolimus (rapamycin) to inhibit TOR.
Results

Histopathology
Biopsies of the epidermal nevus showed characteristic parakeratotic areas, acanthosis and papillomatosis. Subcutaneous biopsies showed bundles of muscle separated by enlarged areas of adipose and fibrous tissue. In all specimens, there was an increase in vascularity ranging from sinusoidal vessels to large arteries and veins. Cheek specimens exhibited dense fibrous lipomatous tissue with mixed portions of salivary gland and striated muscle tissue. No lymphatic involvement was observed. Nerve hypertrophy was noted in all biopsied tissues. The most prominent feature in all of the skin specimens from the overgrowth side was an overabundance of nerves not observed in tissues from the normal side ( Figure 2) . Nerves under the skin, but not under the nevus, had a distinctive neuromatous appearance with lipocyte infiltration, abnormally thickened nerve trunks and increased number of nerves per unit area. Immunocytochemistry with the S100 antibody showed a high concentration of Schwann cells in the affected dermis (Figures 2a-d) . Hyperplastic bone had a wide cortical plate and an increased number of osteocytes (Figures 2d-f ).
Cell size and number differences Primary cell cultures from the hyperplastic side(O) and normal side HFH bones were morphologically indistinguishable (Figures 3a-d) . Hyperplastic and normal cells (Figures 2c and d) showed a maximal difference at 70% confluence during the first five passages: a 2.1-fold increase in size for HFH cells and a 2.4-fold increase in cell number. At 90% confluence, the difference was less: a 1.3-fold increase in size and 1.4-fold increase in HFH cell number. Cells at 70% confluence during the third passage were used for comparisons of gene expression. Both hyperplastic and normal HFH cells formed bone upon subcutaneous transplantation into immunocompromised mice.
Microarray analysis
When the Affymetrix Human HG-U95 Av.2 microarrays were compared using a twofold screen, 70 genes differed; a 1.5-fold screen produced 254 hyperplastic genes that either increased or decreased compared with the normal side cells. The top functions were related to cancer and cell proliferation of mesenchymal cells. The Ingenuity Pathway Analysis identified the IGF-I and glucocorticoid receptor as key pathways. In addition, 20 cell cycle regulator proteins were identified in the 1.5-fold screen that predicted a decrease in G2/M transition. There was a 40% relative reduction in PTEN expression in cells from hyperplastic side compared with the normal side. 
Genetic testing and PTEN mutational analysis
Cytogenetic analysis revealed no chromosomal abnormalities for this patient. There were also no deletions or missense mutations in the PTEN exons; however, a novel C/G germline missense mutation was detected in the promoter at position À 1059 relative to the translational start site. This mutation lies between the Erg-1 (949-937) and p53 ( À 1190 to 1157) binding sites in the promoter region ( Figure 4 ).
Sirolimus treatment of cells in primary culture
When cells from the overgrown side were exposed for 72 h to sirolimus at 50 ng ml À 1 , the cells reverted to normal size, cell proliferation and protein content. Sirolimus compensated for the difference between overgrown and normal side by reducing the cell number of hyperplastic cells in primary cultures by 35.5%, by decreasing the protein content by 25.3% ( Figure 4b) and by shifting the cell size toward a smaller cell size (Figure 4c ).
Materials and Methods
This study was performed at the request of the patient's parents to better understand the etiology of HFH.
Patient diagnosis and history
This patient presented at Childrens Hospital Los Angeles as a newborn with a 'left swollen cheek'. With growth, his left forehead and malar region of the face became asymmetric and enlarged despite three surgical debulking procedures Missense mutation in the PTEN promoter K Yamazaki et al ( Figure 1 ). There was no family history of facial overgrowth or hamartoma. He had a negative abdominal ultrasound and did not have additional orthopedic anomalies. At age 7 years, he had asymmetric hyperplasia of the tongue, tonsil, dentition, gingiva and cheek mucosa, as well as a distinct linear nevus covering the left cheek that extended to the postauricular region, dental crossbites, a left-sided tongue thrust and inferiorly displaced oral commissure, left eye presbyopia, left chronic otitis media and decreased motion of the left side of the face with animation. Two features not common to HFH were the epidermal nevus and left-sidedness of the anomaly. This patient lacked malformations of the extremities and cerebriform folds of the skin that are associated with the Proteus syndrome. 28, 29 On radiographs, the skeletal borders of the growing bone were more consistent with expansive hyperplasia rather than ragged infiltrative lesions associated with the Proteus syndrome. Based on these features, the patient's condition was diagnosed as HFH rather than the Proteus syndrome.
Derivation of bone marrow stromal cells from surgical specimens Patient consent for the use of tissue samples was obtained by Institutional Review Board-approved protocols. During surgical debulking, 3-18 mm of bone was removed from contralateral zygomatic regions of the maxilla and immediately placed in sterile growth medium. Bone marrow stromal cells were isolated and propagated in vitro according to a previously published technique. 30 Briefly, bone marrow was scraped from trabecular bone, pipetted to break up cell aggregates and filtered through a 70 mm nylon strainer (Bectin Dickinson, Franklin Lakes, NJ, USA) before culturing. A single-cell suspension of bone marrow cells was cultured in a growth medium consisting of a-MEM (a-minimum essential medium; Invitrogen, Grand Island, NY, USA), 2 mM L-glutamine, 100 U ml À 1 penicillin, 100 mg ml À 1 streptomycin sulfate (Biofluids, Rockville, MD, USA) and 20% fetal bovine serum of a preselected lot (Equitech-Bio, Kerrville, TX, USA). The cells were incubated at 37 1C in 100% humidity and 5% CO 2 . Cell cultures derived from Missense mutation in the PTEN promoter K Yamazaki et al the overgrowth side were labeled 'hyperplastic HFH'. Cells derived from the unaffected side of the head were labeled 'normal HFH'. Third passage cells were used for in vivo transplantation assays to analyze their osteogenic potential 30 and for cell growth and gene expression assays. Frozen cell stocks were stored in 44% a-MEM, 50% fetal bovine serum, 1% penicillin/streptomycin and 5% dimethylsulfoxide (Sigma, St Louis, MO, USA) and carefully thawed for further analysis. Osteogenic potential was assayed by in vivo transplantation of single colonies into immunocompromised mice.
30,31
Flow cytometry To measure cell size, hyperplastic and normal HFH cell cultures were seeded at the same concentration and compared by flow cytometry when the cells reached 50%, 70% and 90% confluence based on manual cell counts. Trypsinized cells (10 6 ) were collected and scanned for relative cell size measurement in a flow set for forward light scatter and size scatter at the Flow Cytometry Core Facility, Institute of Genetic Medicine, USC.
Chromosome analysis
High-resolution chromosome studies were performed on HFH cell cultures at the Children's Hospital Los Angeles Cytogenetics Laboratory.
PTEN gene sequencing PCR-based denaturing gradient gel electrophoresis and direct DNA sequencing of all nine PTEN exons and flanking intronic regions, deletion analysis of the PTEN gene and promoter sequencing were performed according to Zhou et al. 21 The full 600 bp PTEN promoter was sequenced from positions À 1344 to À 745 relative to the translational start site. A missense mutation with a C to G base substitution was identified at position À 1058.
Microarray RNA was column-purified, quantitated and reverse transcribed for microarray hybridization and analysis using Affymetrix Human HG-U95 Av.2 microarrays. RNA integrity was tested by 3 0 to 5 0 probe signal ratio of b-actin and GAPDH genes. Three microarray comparisons were performed between hyperplastic and normal HFH cell cultures grown to 70% confluence and analyzed using Ingenuity Pathway Analysis softwares (Redwood City, CA, USA). 
Real-time PCR
Western blot protein analysis
Whole-cell lysates from cell cultures were prepared by the boiling method, electrophoresed in 12% polyacrylamide gels (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) and electroblotted onto polyvinylidene difluoride membranes, and then blocked for 1 h, exposed to primary antibodies at 100 mg per blot and secondary horseradish peroxidase-conjugated goat antirabbit IgG for 1 h at room temperature, reacted with substrate (Luminol/H 2 O 2 ) according to the manufacturer's protocol (Roche, Indianapolis, IN, USA) and detected with Kodak X-Omat AR film (Kodak, Rochester, NY, USA). Primary antibodies directed against PTEN (Biocascade, Winchester, MA, USA), TOR (Cell Signaling, Woburn, MA, USA), phosphorylated ribosomal S6 kinase (pS6K), b-actin and GAPDH (the last three from Santa Cruz Biotechnologies, Santa Cruz, CA, USA) were used at 50-100 mg per blot. Protein content was analyzed by the Bradford assay (Bio-Rad Labs, Hercules, CA, USA).
Akt/PKBa kinase immunoprecipitation assay A non-radioactive Akt/PKBa Kinase Immunoprecipitation Assay Kit (Upstate Cell Signaling Solutions, Lake Placid, NY, USA) was designed to measure phosphotransferase activity in an immunocomplex formed between the Akt/PKBa domain antibody and active Akt/PKBa. Immunoprecipitates were detected by an antiphospho-Akt antibody.
Sirolimus treatment of cell cultures
Overgrowth HFH and normal HFH cells were cultured at the same initial cell density (1 Â 10 5 cells per ml) with 50 ng ml À 1 sirolimus for 24, 48 and 72 h and harvested for manual cell count, flow cytometry analysis (1 Â 10 6 cells) and for determination of protein content by the Bradford assay.
Discussion
The cell proliferation and overgrowth of cells isolated from bone biopsies corroborate a study by Yoshimoto et al. 32 on osteoblast cell cultures from HFH patients, which reported no morphological differences between hypertrophic and normal side cells but showed a threefold increase in cell proliferation on the overgrown side as measured by dysregulation and hemihyperplasia. 33 A novel finding was the histopathology, which also showed an unusually dense number of Schwann cells and blood vessels in the affected soft tissue biopsies and a large number of cells that were immunostained by the S100 antibody that was similar to a report by GomezManzano et al. 34 The PTEN gene and promoter were sequenced because germline PTEN mutations were found in 20% of patients with Proteus and Proteus-like syndromes. 20 This study identified a novel PTEN promoter mutation in a highly conserved region positioned between two putative transcription factor binding sites. This mutation is in the vicinity of at least three other Cowdenrelated germline promoter mutations that have been shown to affect PTEN protein and enhance Akt phosphorylation. 35 Our experiments suggest that facial overgrowth may result from a downregulation of PTEN rather than a complete loss of PTEN function. With the discovery of germline PTEN mutations associated with hamartoma syndromes (Figure 5 ), Pilarski and Eng 36 proposed that a hamartoma-neoplasia syndrome with a germline PTEN mutation be classified as a PTEN hamartoma syndrome. Inoki et al. 18 proposed that dysregulation of mTOR is the common basis for hamartomas and for cellular hypertrophic disorders. A similar type of classification based on Akt1 has been proposed for the Proteus syndrome. Taken together, facial hamartomas can be grouped under PTEN/Akt1/TOR dysregulation overgrowth conditions.
In Drosophila and mice, TOR homologs Dros and mTor have been shown to regulate cell size. 37 As the TOR protein can be specifically inhibited by sirolimus, changes in TOR protein may lead to a method for suppressing the effects of upstream PTEN signals.
Although the cell culture model appears to replicate the in vivo cell growth and cell proliferation, the number of studies we were able to conduct was limited by our stock of primary cell cultures. Recurrent surgeries for debulking the asymmetry represent periodic opportunities to replenish stocks of HFH and normal cells during reconstructive surgery.
In conclusion, these experiments report a case of HFH with a missense mutation in the PTEN promoter and increased Akt phosphorylation. Primary cell cultures taken from the overgrowth side responded to sirolimus treatment by returning to a cell size and rate of proliferation comparable to the normal side. Animal studies are needed to determine whether HFH due to dysregulation of the PTEN/Akt. TOR pathway can be treated with sirolimus at the TOR branch point.
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